SynbiTECH 2019 | June 24-25th, QEII Centre, London
SynbiTECH 2019 is the only international forum focused on synthetic biology, taking place in the UK in 2019. The event will address the opportunities and challenges associated with building a multibillion-dollar synthetic biology industry that will underpin the fast-growing bioeconomy. The event is designed for senior business leaders from start-ups to multinationals, investors and policy makers.
Maintaining a highly skilled workforce is vital to business; I can’t imagine anyone reading this blog would dispute that. Similarly indisputable is the need for business to keep up with the latest developments in research and technology. Doctoral training partnerships can help your business to achieve both of these goals, by strengthening ties with academia, shedding light on new ways of working, and increasing recruitment of multi-skilled graduates. UKRI-BBSRC believes that partnerships with the users of research are important in shaping our doctoral training programmes through better understanding of industry’s needs, concerns and aspirations. By working with companies, UKRI-BBSRC seeks to train students capable of becoming future leaders in industry.
I attended and participated in the inaugural WuXi Healthcare Forum in Shanghai in March 2019, enabling me to gain a better insight into some of the key trends occurring in innovative life science in China today. Here are a few thoughts that I came away with.
In the last two years China has made a concerted attempt to, and has delivered, fundamental changes to key aspects of its human healthcare market as part of a broader Government push to improve healthcare for the nation and become a leader in biotechnology. They fall into four areas regulation, reimbursement, talent and capital.
I spent last week at the inaugural WuXi Healthcare Forum in Shanghai, and it proved to be a hugely insightful week, with over 2000 global leaders gathered. I spoke on a panel entitled ‘New Era, Golden Opportunities’ where leaders from China and the UK explored how key stakeholders are redefining the innovation narrative – opening up a new era of opportunities and connecting the global life sciences ecosystem. I also attended the British Consulate-General/BioIndustry Association official reception hosted by John Edwards, HM Consul General in Shanghai and Kevin Holland, Minister Counsellor of Life Sciences and Healthcare at the British Embassy in Beijing. You can read a blog on my thoughts from the forum and the other life sciences developments in China here. The UK’s China life sciences tea
In my first blog in this series, I discussed how the Spending Review (SR) would have received a whole lot more attention in normal political times than what it has so far. BIA is working hard to change that. Two weeks ago, we brought together a stellar panel in front of our whole membership to discuss what the life sciences sector can expect from the SR and get our members’ feedback on BIA’s emerging key messages.